Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $73.53 million
- Book Value:
- Revenue TTM:
- $12.74 million
- Operating Margin TTM:
- Gross Profit TTM:
- $10.18 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Adagene Inc had its IPO on 2021-02-09 under the ticker symbol ADAG.
The company operates in the Healthcare sector and Biotechnology industry. Adagene Inc has a staff strength of 259 employees.
Shares of Adagene Inc opened at $1.31 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $1.31 - $1.37, and closed at $1.33.
This is a +0.76% increase from the previous day's closing price.
A total volume of 4,050 shares were traded at the close of the day’s session.
In the last one week, shares of Adagene Inc have slipped by -8.59%.
Adagene Inc's Key Ratios
Adagene Inc has a market cap of $73.53 million, indicating a price to book ratio of 0.4335 and a price to sales ratio of 4.4993.
In the last 12-months Adagene Inc’s revenue was $12.74 million with a gross profit of $10.18 million and an EBITDA of $-81676016. The EBITDA ratio measures Adagene Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Adagene Inc’s operating margin was -651% while its return on assets stood at -26.15% with a return of equity of -55.96%.
In Q2, Adagene Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 188.7%.
Adagene Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Adagene Inc’s profitability.
Adagene Inc stock is trading at a EV to sales ratio of 0.0853 and a EV to EBITDA ratio of 1.2618. Its price to sales ratio in the trailing 12-months stood at 4.4993.
Adagene Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $178.56 million
- Total Liabilities
- $56.46 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Adagene Inc ended 2023 with $178.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $178.56 million while shareholder equity stood at $112.68 million.
Adagene Inc ended 2023 with $0 in deferred long-term liabilities, $56.46 million in other current liabilities, 5657.00 in common stock, $-226476058.00 in retained earnings and $0 in goodwill. Its cash balance stood at $168.04 million and cash and short-term investments were $168.04 million. The company’s total short-term debt was $7,609,251 while long-term debt stood at $9.26 million.
Adagene Inc’s total current assets stands at $175.01 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.87 million compared to accounts payable of $4.67 million and inventory worth $0.
In 2023, Adagene Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Adagene Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Adagene Inc stock is currently trading at $1.33 per share. It touched a 52-week high of $6.06 and a 52-week low of $6.06. Analysts tracking the stock have a 12-month average target price of $12.53.
Its 50-day moving average was $1.39 and 200-day moving average was $1.41 The short ratio stood at 0.38 indicating a short percent outstanding of 0%.
Around 1067.6% of the company’s stock are held by insiders while 971.1% are held by institutions.
Frequently Asked Questions About Adagene Inc
Similar Industry Stocks (Biotechnology)
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company’s product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin’s lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.